Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EDI-M420
- Development stage
- Preclinical
- Lead developer
- Empire Discovery Institute
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
EDI-M420 is a preclinical-stage antisense oligonucleotide (ASO) therapeutic developed by the Empire Discovery Institute (EDI). It is designed to modulate mitochondrial energy metabolism by targeting specific natural RNA sequences. The drug is being investigated for the treatment of lung and cardiovascular diseases, leveraging a platform focused on addressing mitochondrial dysfunction. As an ASO, EDI-M420 likely functions by binding to its target RNA to either trigger degradation or modulate splicing/translation, thereby restoring or enhancing mitochondrial bioenergetics in affected tissues.
Beyond the preview
Go deeper on EDI-M420.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EDI-M420.